JW Lifescience Corporation (KRX:234080)
South Korea · Delayed Price · Currency is KRW 12,620
-290 (-2.25%)
Apr 2, 2026, 3:30 PM KST
JW Lifescience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 28,606 | 43,988 | 28,144 | 14,961 | 12,914 |
Depreciation & Amortization | 18,193 | 15,737 | 15,531 | 14,956 | 13,245 |
Loss (Gain) From Sale of Assets | -49.79 | 31.79 | 205.81 | 95.87 | 362.94 |
Asset Writedown & Restructuring Costs | - | - | - | - | -85 |
Loss (Gain) From Sale of Investments | - | - | 43.5 | - | - |
Loss (Gain) on Equity Investments | - | -10,392 | -6,532 | 4,921 | 4,780 |
Provision & Write-off of Bad Debts | -0.44 | - | - | - | - |
Other Operating Activities | -2,893 | -1,638 | 1,399 | 1,575 | 2,607 |
Change in Accounts Receivable | -552.04 | 17,232 | -2,079 | -21,103 | 2,576 |
Change in Inventory | 3,129 | -5,834 | -1,285 | -1,057 | -4,517 |
Change in Accounts Payable | -2,624 | -4,794 | 3,540 | 2,730 | 1,781 |
Change in Other Net Operating Assets | -3,272 | -3,640 | -1,392 | -2,950 | -3,498 |
Operating Cash Flow | 40,537 | 50,690 | 37,574 | 14,129 | 30,165 |
Operating Cash Flow Growth | -20.03% | 34.91% | 165.94% | -53.16% | -35.48% |
Capital Expenditures | -12,554 | -10,307 | -8,153 | -8,079 | -18,976 |
Sale of Property, Plant & Equipment | 110.56 | 4.9 | 3.7 | 2 | 1.71 |
Cash Acquisitions | - | -49,437 | - | - | - |
Sale (Purchase) of Intangibles | -878.76 | 61.87 | -113.8 | -214.05 | -259.87 |
Investment in Securities | - | 6,516 | 17,036 | -24,755 | -655.91 |
Other Investing Activities | -46.36 | -14,873 | -736.19 | -0.26 | 184.97 |
Investing Cash Flow | -13,369 | -68,034 | 8,037 | -28,247 | -22,805 |
Short-Term Debt Issued | 197,300 | 20,000 | 43,500 | 139,700 | 157,800 |
Long-Term Debt Issued | - | 30,000 | - | 44,185 | 770 |
Total Debt Issued | 197,300 | 50,000 | 43,500 | 183,885 | 158,570 |
Short-Term Debt Repaid | -207,200 | -10,000 | -49,500 | -162,350 | -145,450 |
Long-Term Debt Repaid | -8,658 | -30,481 | -15,566 | -677.41 | -3,483 |
Total Debt Repaid | -215,858 | -40,481 | -65,066 | -163,027 | -148,933 |
Net Debt Issued (Repaid) | -18,558 | 9,519 | -21,566 | 20,857 | 9,637 |
Repurchase of Common Stock | - | - | - | - | -6,749 |
Dividends Paid | -7,742 | -7,742 | -7,742 | -7,742 | -7,917 |
Other Financing Activities | - | -0 | - | -0 | - |
Financing Cash Flow | -26,301 | 1,776 | -29,308 | 13,115 | -5,029 |
Miscellaneous Cash Flow Adjustments | -0 | 2,857 | - | - | -0 |
Net Cash Flow | 867.39 | -12,711 | 16,302 | -1,003 | 2,331 |
Free Cash Flow | 27,983 | 40,383 | 29,421 | 6,049 | 11,189 |
Free Cash Flow Growth | -30.71% | 37.26% | 386.35% | -45.93% | -63.70% |
Free Cash Flow Margin | 10.85% | 18.15% | 14.22% | 3.20% | 6.59% |
Free Cash Flow Per Share | 1806.77 | 2608.20 | 1900.03 | 390.67 | 718.13 |
Cash Interest Paid | 2,737 | 2,101 | 2,869 | 2,949 | 1,253 |
Cash Income Tax Paid | 9,646 | 5,113 | 6,433 | 6,044 | 9,537 |
Levered Free Cash Flow | 33,184 | 5,915 | 26,784 | 8,717 | 10,273 |
Unlevered Free Cash Flow | 34,958 | 7,203 | 28,467 | 10,649 | 11,073 |
Change in Working Capital | -3,319 | 2,964 | -1,217 | -22,381 | -3,658 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.